Le Lézard
Classified in: Business
Subject: ATY

Kaskela Law LLC Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) and Encourages Long-Term REGN Stockholders to Contact the Firm


PHILADELPHIA, July 23, 2020 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) on behalf of the Company's stockholders.

On June 24, 2020, the U.S. Attorney's Office filed a complaint against Regeneron for alleged violations of the False Claims Act.  The complaint alleges that the Company engaged in a sophisticated kickback scheme through which it funneled tens of millions of dollars from a foundation with the goal of covering the co-pay costs of Medicare patients utilizing the Company's Eylea drug.  According to the complaint, this scheme undermined the medical system and wasted taxpayers' monies by causing Medicare to pay out nearly $2 billion for access to the drug.  Further according to the complaint, "[b]ecause the anti-kickback statute, 42 U.S.C. § 1320-7b(b), prohibits such "indirect" kickbacks to subsidize the price of a drug reimbursed by Medicare, Regeneron's conduct was illegal, and senior management knew it."

The investigation seeks to determine whether the members of Regeneron's board of directors breached their fiduciary duties to the Company and its stockholders in connection with the above, including by failing to implement and maintain an effective system of internal controls over operations.

Current Regeneron stockholders who purchased or acquired shares of the Company's stock prior to January 1, 2016 are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq.) at (484) 258 ? 1585, or by email at [email protected], to discuss this investigation and their legal rights and options.  Additional information may also be found at http://kaskelalaw.com/case/regeneron-pharmaceuticals-inc/.

Kaskela Law LLC represents investors in securities fraud, corporate governance, and merger & acquisition litigation.  For additional information about Kaskela Law LLC please visit www.kaskelalaw.com

CONTACT:

D. Seamus Kaskela, Esq.
KASKELA LAW LLC
18 Campus Blvd., Suite 100
Newtown Square, PA 19073
(484) 258 ? 1585
(888) 715 ? 1740
www.kaskelalaw.com 
[email protected]

This notice may constitute attorney advertising in certain jurisdictions.

SOURCE Kaskela Law LLC


These press releases may also interest you

at 21:15
Curio Legacy Ventures, Inc., a Washington DC-based company dedicated to advancing a closed fuel...

at 20:34
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against AST SpaceMobile, Inc. ("SpaceMobile" or "the Company") and certain of its officers....

at 20:26
Growth Opportunity Partners (Growth Opps), a leading community financial institution and Green Bank, and the International Brotherhood of Electrical Workers (IBEW) today announced a groundbreaking agreement to collaborate on the implementation of the...

at 20:14
Vinci Partners Investments Ltd. ("Vinci Partners," "we," "us," or "our"), the controlling company of a leading alternative investment platform in Brazil, announced today that it will release financial results for the first quarter 2024 after market...

at 20:00
OKX Ventures, the investment arm of leading crypto exchange and Web3 technology company OKX, today announced its participation in the 'Runes Incubator.' This program, initiated by OnePiece Labs and supported by Merlin Chain and Franklin Templeton,...

at 20:00
SK hynix Inc. (or "the company", www.skhynix.com) announced today that it has recently signed a memorandum of understanding with TSMC for collaboration to...



News published on and distributed by: